Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Piper Sandler reiterated that Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the stocks to own as the company is poised for transformational growth in 2026.

According to the research firm, the company is staring at tremendous opportunities and a transformational year as it launches key drugs. The remarks follow confirmation of dosing the first patient in Phase ½ of a study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors.

The BRAVESST2 study seeks to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682 from the nonpeptide drug conjugate (NDC) platform. Crinetics is in a strong financial position, with more cash than debt on the balance sheet, enabling it to accelerate pipeline development.

“We developed CRN09682 to address the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors,” said Stephen Betz, Chief Scientific Officer and Co-Founder of Crinetics, in the press release.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage drug company focused on developing oral treatments for rare endocrine (hormonal) diseases and tumors, including acromegaly, Cushing’s disease, carcinoid syndrome, and congenital adrenal hyperplasia (CAH), using small molecules and peptide agonists that target hormone receptors.

While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.